Patent: 10,066,269
✉ Email this page to a colleague
Summary for Patent: 10,066,269
Title: | Methods for detecting and treating multiple myeloma |
Abstract: | The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma. |
Inventor(s): | Villota Arcos; Claudio E. (Santiago, CL), Villegas Olavarria; Jaime E. (Santiago, CL), Burzio Menendez; Veronica A. (Santiago, CL), Burzio Eriz; Luis O. (Santiago, CL) |
Assignee: | ANDES BIOTECHNOLOGIES GLOBAL, INC. (Burlingame, CA) |
Application Number: | 14/776,260 |
Patent Claims: | see list of patent claims |
Details for Patent 10,066,269
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2033-03-14 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2033-03-14 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2033-03-14 | |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2033-03-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |